A retrospective, observational study comparing efficacy of rifaximin dosing (400 mg thrice daily) compared to newer dosing (550 mg twice daily) in patients with recurrent hepatic encephalopathy.

Trial Profile

A retrospective, observational study comparing efficacy of rifaximin dosing (400 mg thrice daily) compared to newer dosing (550 mg twice daily) in patients with recurrent hepatic encephalopathy.

Completed
Phase of Trial: Phase IV

Latest Information Update: 16 Feb 2017

At a glance

  • Drugs Rifaximin (Primary) ; Lactulose; Metronidazole
  • Indications Hepatic encephalopathy
  • Focus Therapeutic Use
  • Most Recent Events

    • 16 Feb 2017 New trial record
    • 08 Feb 2017 Results published in the Journal of Gastroenterology and Hepatology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top